Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor-Reference-Cited by-同舟云学术

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor

Published:2019-08 Issue: Volume:136 Page:104938
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Gu Yi,Sai Yang,Wang Jian,Yu Meijing,Wang Guanglin,Zhang Li,Ren Hongcan,Fan Shiming,Ren Yongxin,Qing Weiguo,Su Weiguo

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference40 articles.

1. Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process;Choo;Xenobiotica,2011

2. A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC);Choueiri;J. Clin. Oncol.,2017

3. A Safety and Dose-Finding Study of JNJ-38877605 in Patients with Advance or Refractory Solid Tumor;ClinicalTrials, N.I.o.H,2013

4. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research;Danhof;Trends Pharmacol. Sci.,2008

5. Physiological parameters in laboratory animals and humans;Davies;Pharm. Res.,1993

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Savolitinib: A Promising Targeting Agent for Cancer;Cancers;2023-09-25

2. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?;International Journal of Molecular Sciences;2023-06-14

3. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers;Clinical Pharmacology in Drug Development;2023-02-19

4. Savolitinib for non-small cell lung cancer;Drugs of Today;2023-01

5. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review;Cancers;2022-12-12